Ketogenic Diet for Kidney

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Virginia, Charlottesville, VA
Kidney+1 More
Ketogenic Diet - Behavioral
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This study seeks to assess the kidney health effects of short-term healthful ketogenic diet in young, overweight adults.10 overweight (BMI 25-30 kg/m2) adult participants (ages 20-40 years) without major chronic conditions including diabetes, kidney, cardiac, or liver disease will receive an isocaloric, high protein and low carbohydrate ketogenic diet for 2 weeks.

Eligible Conditions

  • Kidney
  • Ketogenic Dieting

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Day 0 and day 15 of the intervention

Day 15
Within person change in microbiome composition by 16s rRNA sequencing comparing Day 15 to pre-intervention
Within person change in urine metabolites comparing Day 15 to pre-intervention
Within-person change in MCP-1 comparing Day 15 to pre-intervention
Within-person change in UACR comparing Day 15 to pre-intervention
Within-person change in eGFR-Cr comparing Day 15 to pre-intervention
Within-person change in eGFR-Cr-and-Cystatin comparing Day 15 to pre-intervention
Within-person change in eGFR-Cystatin comparing Day 15 to pre-intervention
Within-person change in urine KIM-1 comparing Day 15 to pre-intervention
Within-person change in urine NGAL comparing Day 15 to pre-intervention

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Ketogenic Diet
1 of 1
Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Ketogenic Diet · No Placebo Group · N/A

Ketogenic Diet
Behavioral
Experimental Group · 1 Intervention: Ketogenic Diet · Intervention Types: Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketogenic Diet
2016
Completed Phase 2
~440

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: day 0 and day 15 of the intervention
Closest Location: University of Virginia · Charlottesville, VA
Photo of university of virginia 1Photo of university of virginia 2Photo of university of virginia 3
2004First Recorded Clinical Trial
0 TrialsResearching Kidney
526 CompletedClinical Trials

Who is running the clinical trial?

University of VirginiaLead Sponsor
670 Previous Clinical Trials
1,420,399 Total Patients Enrolled
1 Trials studying Kidney
20 Patients Enrolled for Kidney
Sibylle Kranz, PhD RDN FTOSPrincipal InvestigatorUniversity of Virginia

Eligibility Criteria

Age 18 - 65 · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are overweight.
You have lived in the greater Charlottesville/Albemarle area for more than six months out of the last year.
You have normal kidney function at baseline, eGFR ≥60 ml/min/1.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References